Brain and Behavior · 2022 · 15 citations · 12 references
MedicineNeurologyNeurosurgeryEvidence-based PracticeFunctional NeurosurgeryGood Clinical PracticeClinical TrialsHeadache ManagementSubarachnoid Hemorrhage ManagementSubdural HematomaChronic Subdural HematomaComparative Clinical TrialsIndications For SurgeryOperative TreatmentSubdural Hematoma CareSubdural Hematoma Clinical PresentationSubdural Hematoma DiagnosisSubdural Hematoma Epidemiology
BACKGROUND: Chronic subdural hematoma (CSDH) is a frequent pathological entity in daily clinical practice. However, evidence-based CSDH-guidelines are lacking and level I evidence from randomized clinical trials (RCTs) is limited. In order to establish and subsequently implement a guideline, insight into current clinical practice and attitudes toward CSDH-treatment is required. The aim is to explore current practice and attitudes toward CSDH-management in the Netherlands. METHODS: A national online survey was distributed among Dutch neurologists and neurosurgeons, examining variation in current CSDH-management through questions on treatment options, (peri)operative management, willingness to adopt new treatments and by presenting four CSDH-cases. RESULTS: One hundred nineteen full responses were received (8% of neurologists, N = 66 and 35% of neurosurgeons, N = 53). A majority of the respondents had a positive experience with burr-hole craniostomy (93%) and with a conservative policy (56%). Around a third had a positive experience with the use of dexamethasone as primary (30%) and additional (33.6%) treatment. These numbers were also reflected in the treatment preferences in the presented cases. (Peri)operative management corresponded among responding neurosurgeons. Most respondents would be willing to implement dexamethasone (98%) if equally effective as surgery and tranexamic acid (93%) if effective in CSDH-management. CONCLUSION: Variation was found regarding preferential CSDH-treatment. However, this is considered not to be insurmountable when implementing evidence-based treatments. This baseline inventory on current clinical practice and current attitudes toward CSDH-treatment is a stepping-stone in the eventual development and implementation of a national guideline.
12
Marjolein Lugtenberg, Judith M Zegers-van Schaick, Gert P. Westert et al. · Implementation Science · 2009 · 486 citations · Full text
Trial of Dexamethasone for Chronic Subdural Hematoma
Peter J. Hutchinson, Ellie Edlmann, Diederik Bulters et al. · New England Journal of Medicine · 2020 · 267 citations · Full text